Key Highlights
- Wells Fargo elevated OSCR from Underweight to Equal Weight, increasing the price target from $11 to $20
- Shares are currently trading around $20.50, reflecting a 43% gain year-to-date
- In Florida, which represents approximately 64% of Oscar’s premium revenue, membership declined 13.5% year-over-year while medical loss ratios strengthened by 370 basis points
- First quarter 2026 earnings per share reached $2.07, significantly exceeding the analyst consensus of $1.06
- Wall Street sentiment has turned more positive for 2026, though longer-term outlook remains uncertain
Oscar Health (OSCR) experienced a significant midweek rally following a Wells Fargo upgrade paired with a substantial price target increase, propelling shares upward by approximately 14% during the trading session.
Stephen Baxter, analyst at Wells Fargo, elevated his rating on OSCR from Underweight to Equal Weight while simultaneously boosting his price objective to $20 from the previous $11 target. At the time of the announcement, shares were changing hands near the $20.50 level.
The rating adjustment followed Wells Fargo’s comprehensive analysis of statutory regulatory filings, which revealed that both enrollment figures and morbidity patterns across health insurance exchanges are performing ahead of expectations for 2026.
The broader sector is demonstrating significant progress in medical loss ratio performance, while insurers appear to be adopting more conservative approaches to risk adjustment accounting compared to the previous yearāa development Wells Fargo interprets favorably.
Baxter indicated the firm has gained increased confidence regarding the exchange market’s direction through 2026, though he emphasized that forecasting accuracy diminishes considerably beyond that timeframe. Payment integrity remains an area requiring ongoing monitoring.
Performance in the Sunshine State
Florida stands as Oscar’s dominant geographic market, contributing approximately 64% of total premium income. While enrollment in the state contracted 13.5% compared to the prior year, the medical loss ratio demonstrated impressive improvement, gaining 370 basis points year-over-year.
Wells Fargo’s analysis also identified potentially 640 basis points of conservative risk adjustment accounting practices in Oscar’s Florida operationsāa stark contrast to the methodology employed during the previous year.
Heading into Wednesday’s session, Oscar had already compiled an impressive 43% gain since the start of the year, with shares hovering around $20.50 before the upgrade announcement provided additional momentum.
Despite the strong upward movement, the stock exhibited some intraday volatility as market participants balanced the encouraging near-term fundamentals against the uncertainty surrounding performance beyond 2026.
First Quarter Performance and Executive Transition
Oscar Health delivered first quarter 2026 earnings of $2.07 per share, substantially surpassing Wall Street’s $1.06 projection. Conversely, top-line revenue fell short of analyst expectations during the quarter.
The analyst community anticipates Oscar Health will achieve profitability for the full 2026 fiscal year, with three analysts having recently increased their earnings projections.
Regarding organizational changes, co-founder Mario Schlosser transitioned away from his operational responsibilities as President of Technology and Chief Technology Officer. His new position as Co-Founder and Advisor to the CEO allows him to focus on artificial intelligence initiatives and digital health innovation while maintaining his board seat.
The company currently commands a market capitalization approaching $6.37 billion, with typical daily share volume averaging approximately 7.16 million.
Wells Fargo’s more favorable stance represents part of an emerging pattern among Wall Street analysts who are adopting increasingly optimistic views on Oscar’s near-term prospects, driven by encouraging early 2026 exchange market indicators.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
